Fresh analysis indicates that people who discontinue popular GLP-1 drugs like Mounjaro or Wegovy may regain shed pounds much more quickly than those who stop traditional lifestyle plans.
Findings released in a major medical journal shows that while obese individuals often shed substantial amounts of their body weight while undergoing treatment, the weight comes back at an estimated rate of 0.8 kg per month once they quit.
"Users buying such drugs should be aware of the danger of fast rebound weight gain when the medication concludes," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery means a return to pre-treatment weight within about a year and a half.
Comparing Therapies
The analysis, which looked at dozens of trials involving thousands of patients, contrasted the effects of these new drugs with other pills.
The team note that people who lose weight through dieting generally have a slower creep back—perhaps 0.1 kg a month—once they finish.
Understanding the Quick Rebound
Nutrition scientists propose the way of the injections explains the heightened regain.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which controls appetite.
"Sustained high doses of GLP-1 levels several times higher than the body's typical production might result in the body to generate a reduced amount of its endogenous hormone, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Stopping of this GLP-1 'fix' results in hunger is unsuppressed, making overeating much more probable."
An Ongoing Disease?
Health authorities recommend the jabs for people with weight-linked medical conditions, alongside recommended diet and exercise modifications.
Professionals say that, given the likelihood of weight regain, the therapy might need to be ongoing.
This view is echoed by pharmaceutical companies, who state that the findings "highlight the persistent character of excess weight," akin to managing diseases like hypertension.
Patient Testimonies
Users who have stopped the medication explain a sudden return of hunger.
"It felt as if a trigger that goes on and I was suddenly ravenous," said a patient.
This difficulty is compounded if individuals have not established permanent dietary or behavioural changes during treatment.
Significant Interest
Recent estimates indicate that a significant number of people in the UK have tried weight-loss jabs in the past year, with desire continuing to grow.
- Adoption is higher among women than males.
- The 40s and 50s demographic shows the greatest level of interest.
- Many access the drugs through private prescriptions rather than the NHS.
Ultimately, clinicians emphasize that while GLP-1 drugs are powerful tools for weight loss, they are not a permanent fix and lasting health benefits relies on combined behavioural management.
